Intelligent Bio Solutions Reports Record Q1 Fiscal 2027 Revenue of $1.39 Million, Up 25% Year-Over-Year
Intelligent Bio Solutions Inc. reported record fiscal first quarter 2027 revenue of $1.39 million, up 25% year-over-year and 21% sequentially, marking the sixth consecutive quarter of year-over-year growth and the third consecutive quarter above $1 million. Gross profit margin expanded to 54.5% from 46.6% in the prior-year quarter, driven by higher-margin cartridge sales which grew 32% year-over-year and represented 61% of total revenue. The company submitted its FDA 510(k) premarket notification for the Intelli...
Key takeaways
Revenue: Record quarterly revenue of $1.39 million, up 25% YoY and 21% sequentially; third consecutive quarter above $1 million.
Cartridge sales: $845,583, up 32% YoY and 35% sequentially, representing 61% of total revenue and driving most of the revenue growth.
Gross margin: 54.5%, up from 46.6% in prior-year quarter, reflecting manufacturing efficiencies and higher-margin cartridge mix.
Net loss: $(2.66) million attributable to INBS, compared to $(2.98) million in Q1 fiscal 2026; net loss per share of $(0.86) versus $(3.49) in the prior-year quarter.
FDA 510(k): Submitted premarket notification in September 2026 for the Intelligent Fingerprinting Drug Screening System for detection of codeine, with accuracy above 98%, sensitivity above 94%, and specificity of 100%.
Customer base: 516 active customer accounts as of September 30, 2026, including 27 new accounts added during the quarter, with a reader installed base of 1,978 units.
Cash position: $5.93 million at September 30, 2026, compared to $3.99 million at June 30, 2026.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow INBS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.